Find updates on the work of our researchers here, as well as news about recent advances in Alzheimer's science, funding and awareness.

Research Update: May 2008

Two papers, supported in part by Cure Alzheimer’s Fund,  have just been published in two leading research journals. The findings show links between certain kinds of anesthesia and pathological features of Alzheimer’s disease.

Alzheimer's Drugs on the Horizon

Part I. Disease-Modifying Drugs Targeting A-beta

By Dr. Rudolph Tanzi, Massachusetts General Hospital

Recent developments regarding drugs aimed at treating and preventing Alzheimer’s disease (AD) by targeting the neurotoxic peptide Abeta.

This article, the first in a series of pieces reviewing promising new AD drugs in development, focuses on novel therapies based on the “A-beta Hypothesis of AD”.  These drugs are aimed at retarding disease progression by curbing the accumulation of A-beta, and particularly, A-beta42, in the brain.

The Basics of Drug Discovery

The path from research discovery to drug development can be a long one. Current estimates target the time for an Alzheimer’s drug to get to market at around 12 years. However, with new technological advances in such areas as genetics, we are optimistic
that scientific opportunities have never been greater to reduce this timeline significantly.
In his article, Dr. Tanzi highlights some of the promising developments on the immediate horizon. We’ve compiled the following background information on the drug development process in the United States to explain the progress of a drug to market.


Novel Therapies for Alzheimer's Disease Based on Early Onset Genes

Supplemental Information for Senate Special Committee on Aging Hearing


Alzheimer’s disease (AD), the most common form of dementia, was first described roughly one hundred years ago in Bavaria by Dr. Alois Alzheimer in his presentation of an early-onset (<60 years) case.  AD is a progressive and fatal neurodegenerative disease that impairs memory and overall cognition. There are more than 5 million documented patients according to best estimates, with some experts suggesting that may be only 20% of the total number actually affected. The number of new cases grows by more than 10% per year. Alzheimer’s disease is the seventh leading cause of death for people of all ages, the fifth leading cause of death in people age 65 and older, and is the only one of the major diseases (heart disease, breast and prostate cancer and stroke) to be increasing in mortality; up almost 33% from 2002 to 2004. Medicare expenditures for Alzheimer’s and other dementias in 2005 were $91 billion; this total is projected to increase to $160 billion by 2010. State and federal Medicaid spending for nursing home care for people with Alzheimer’s and other dementias was estimated at $21 billion in 2005, and is projected to increase to $24 billion by 2010. Given these estimates and no significant containment or decrease in Alzheimer’s, Medicaid and Medicare expenses for Alzheimer’s and related dementias will be approximately $184 billion by 2010, or approximately 27% of the entire combined anticipated expenditure for Medicare and Medicaid in 2010.

The Search for New Ways to Treat Alzheimer's Disease

By John R. Cirrito, Ph.D., and David M. Holtzman, M.D.
Microdialysis Core Facility, Department of Neurology, Hope Center for Neurological Diseases, Washington University, St. Louis, MO

A major contributing factor in Alzheimer’s disease is the elevation of a protein called amyloid-β, or Aβ. Since high levels of Aβ play a role in the disease, many research groups around the world are developing therapies designed to lower the levels of this protein. With the help of Cure Alzheimer’s Fund, our group initiated an ambitious project to discover new drugs that reduce Aβ levels. Our approach is to test drugs in living animals (mice). While this process is time-consuming, it enables us to discover entirely new classes of compounds that traditional drug screening methods typically might overlook.

Alzheimer's Genome Project Pre-publication Summary


Alzheimer’s disease (AD) is the most common cause of dementia in the elderly and a burgeoning unmet medical need that will only worsen as the average lifespan continues to increase. The prevalence of AD increases with every decade after the age of 60 and ~ 20% of the population can expect to get this devastating disease in their lifetime given the current average lifespan of  ~78 years. AD is strongly influenced by inherited factors. In fact, after age, the greatest risk factor for AD is family history. Studies of several thousand pairs of twins have revealed that at least 80% of Alzheimer’s disease involves the inheritance of risk-conferring gene defects—either gene mutations that directly cause the disease, or gene variants that increase susceptibility. To date, we know the identity of four AD genes. Over the last two decades, studies of these four genes, and particularly the three early-onset AD genes co-discovered by Cure Alzheimer’s Fund Research Consortium Chairperson, Dr. Rudy Tanzi, have guided virtually all laboratory research aimed at understanding AD and developing novel therapeutics. As invaluable as the known AD genes have been to solving the mystery of AD and guiding new therapeutic interventions, these four genes account for only 30% of the inheritance of Alzheimer’s disease. While the three early onset AD genes (APP,PSEN1, and PSEN2) account for roughly half of familial early-onset AD, for the most common late-onset (>60 years) form of AD, only one gene has thus far been established to increase susceptibility. This gene is known as the apolipoprotein E (APOE) gene. Since the discovery of the association between AD risk and the E4 variant of the APOE gene, increasing evidence indicates that this variant is neither sufficient nor necessary to cause the disease. We know that APOE works together with other genes to influence one’s inherited risk for AD. To date, the identity of the additional AD genes, which account for 70% of the genetic basis of AD, has remained unknown.

The Cure Alzheimer's Fund National Alzheimer's Disease Research Strategy

Prepared by:

Rudolph E. Tanzi, Ph.D.
Chairperson, Cure Alzheimer’s Fund Research Consortium
Joseph P. and Rose F. Kennedy Professor of Neurology
Harvard Medical School,
Director, Genetics and Aging Research Unit,
MassGeneral Institute for Neurodegenerative Disease
Department of Neurology
Massachusetts General Hospital
114 16th Street
Charletown, MA 02129

Timothy W. Armour
President and CEO
Cure Alzheimer’s Fund
34 Washington Street Suite 300
Wellesly Hills, MA 02481

The overarching goal of a national AD research strategy is to reach a cure most efficiently by accelerating studies aimed at identifying and characterizing all of the genes that influence susceptibility to AD, placing highest priority on those that will most readily lead to effective therapeutics for the treatment and prevention of AD.

Over the next decade, the influx of roughly 50 billion dollars into AD research should allow us by 2020 to identify all of the genes involved in AD susceptibility, and to arrive at a cure based largely on prevention.

Research Papers Supported By Cure Alzheimer's Fund

This is a list of papers funded by Cure Alzheimer's Fund. It also includes “layperson” descriptions of each paper. We are grateful to the researchers for translating the work of their papers into language more accessible to most of us than the more precise technical language useful to them and their peers.

We thank all the researchers and lab personnel for their dedication and commitment to the common mission of ending this disease, and we congratulate all of them for the important work reflected in these papers.

We also are grateful to all of those who literally made this work possible. Without those of you who have supported Cure Alzheimer’s Fund projects through your generosity, these papers and the forward momentum they represent would not exist.


Major Findings Linking New Genes to Alzheimer's Disease Announced in Publication of Four Papers

Four papers published this fall in leading science journals refer to the identification of new genes that confer risk for, or protection against, Alzheimer’s disease.


Lifetime Achievement Awards in Alzheimer's Disease Research Given to Cure Alzheimer's Fund Research Consortium Member Virginia Lee

Virginia Lee

Khalid Iqbal, PhD was one of the founders of the International Conference for Alzheimer’s Disease in 1988. A Lifetime Achievement Awards named in his honor is given to an outstanding scientist who has dedicated his/her career to helping millions around the world through research. The Khalid Iqbal Lifetime Achievement Award was awarded to Cure Alzheimer's Fund Research Consortium member and funded researchers Virginia M.-Y. Lee. Dr. Lee is director of Penn’s Center for Neurodegenerative Disease Research. Dr. Lee's research focus includes determining the genesis and roles of various normal and abnormal brain proteins (amyloid, tau, etc.) thought to be the keys to the cause and progression of numerous brain diseases, including Alzheimer's.